Drug companies in Wales have said that Brexit is wasting time and money that could be otherwise spent on developing new medicines.
The BBC reported that the industry in Wales has put in “robust plans” in case of a no-deal Brexit, as talks with the EU are deadlocked over the issue of the Irish border.
Several large pharma companies have operations in Wales, and in 2015 the Welsh government established a Life Sciences Hub in Cardiff to support the industry’s activities.
Click here to READ MORE
But Dr Richard Greville, the Welsh branch director of the Association of the British Pharmaceutical Industry (ABPI) told the BBC that the deadlock is a “challenge” for pharma.
Pharma companies are vulnerable to changes enforced by Brexit because they are currently regulated by the European Medicines Agency (EMA).
This is likely to change after Brexit, with a worst-case scenario being the UK regulator taking on all the work previously done by the EMA.
In this case pharma companies would have to get authorisations for new drugs in the EU and separately in the UK, as well as overcoming any trade restrictions that could come into play in the event of no-deal.
This could lead to extra costs and potential delays getting drugs to patients in Wales, said Greville, who echoed concerns expressed by pharma companies operating across the UK in the build-up to Brexit.
Greville said: “Because of the global nature of the industry, the supply, the frictionless movement of goods is absolutely critical because some medicines are manufactured in the UK, some medicines are manufactured in the EU and some medicines are manufactured in the rest of the world.
“But, basically, if you are a patient in Wales who needs access to that medicine no matter where it’s been manufactured you want the access to that medicine to be unrestricted.”
Read Full Article: Brexit wasting time and money, say Welsh pharma companies